OverviewSuggest Edit

Intersect ENT is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The Company markets the first and only drug-releasing sinus implants, PROPEL and PROPEL mini, which are clinically proven to improve surgical outcomes for patients with chronic sinusitis. The products release an advanced steroid with anti-inflammatory properties directly into the sinus lining, then dissolve, maintaining the open passages created in ethmoid sinus surgery. In addition, Intersect ENT is pursuing clinical trials designed to support expanded indications and to assess two new investigational drug-eluting implants to provide ENT physicians with additional options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.
TypePublic
Founded2003
HQMenlo Park, CA, US
Websiteintersectent.com
Employee Ratings2.7
Overall CultureD

Latest Updates

Employees (est.) (Dec 2019)402(+3%)
Revenue (FY, 2019)$109.1 M
Share Price (Jan 2021)$25.2 (+5%)
Cybersecurity ratingBMore

Key People/Management at Intersect ENT

Thomas A. West

Thomas A. West

President and Chief Executive Officer
Patrick Broderick

Patrick Broderick

Executive Vice President, General Counsel and Corporate Secretary
Reyna Fernandez

Reyna Fernandez

Chief Human Resources Officer
Rich Kaufman

Rich Kaufman

Chief Operating Officer & Senior Vice President R&D
Christine Kowalski

Christine Kowalski

Executive Vice President & Chief Operating Officer
Randy Meier

Randy Meier

Executive Vice President & Chief Financial Officer
Show more

Intersect ENT Office Locations

Intersect ENT has an office in Menlo Park
Menlo Park, CA, US (HQ)
1555 Adams Dr
Show all (1)

Intersect ENT Financials and Metrics

Intersect ENT Revenue

Embed Graph
View revenue for all periods
Intersect ENT's revenue was reported to be $109.14 m in FY, 2019
USD

Revenue (Q3, 2020)

22.7m

Gross profit (Q3, 2020)

14.9m

Gross profit margin (Q3, 2020), %

65.5%

Net income (Q3, 2020)

(11.5m)

EBIT (Q3, 2020)

(11.4m)

Market capitalization (13-Jan-2021)

825.2m

Closing stock price (13-Jan-2021)

25.2

Cash (30-Sept-2020)

56.9m

EV

777.3m
Intersect ENT's current market capitalization is $825.2 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

38.6m61.6m78.7m96.3m108.5m109.1m

Revenue growth, %

60%28%

Cost of goods sold

10.2m12.3m13.0m15.5m22.6m21.8m

Gross profit

28.4m49.3m65.7m80.8m85.9m87.4m
Quarterly
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

13.4m34.8m9.9m19.8m9.5m20.7m

Accounts Receivable

8.3m11.5m14.4m16.6m19.6m19.1m

Prepaid Expenses

2.9m2.7m2.3m

Inventories

951.0k1.5m1.3m8.5m11.6m17.0m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(18.4m)(26.6m)(25.2m)(16.4m)(22.9m)(43.0m)

Depreciation and Amortization

1.2m1.5m1.9m2.7m

Inventories

(541.0k)(544.0k)(1.7m)(2.9m)(2.5m)(5.1m)

Accounts Payable

645.0k(230.0k)1.2m203.0k2.1m(1.2m)
USDQ2, 2014

Financial Leverage

-0.2 x
Show all financial metrics

Intersect ENT Operating Metrics

Intersect ENT's Patients was reported to be 150 k in FY, 2016.
FY, 2016

Accounts

2.40 k

Patents (US)

30

Patents Pending

37

Patients

150 k
Show all operating metrics

Intersect ENT Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

SecurityScorecard logo

Intersect ENT Online and Social Media Presence

Embed Graph

Intersect ENT Company Culture

  • Overall Culture

    D

    58/100

  • CEO Rating

    D-

    60/100

  • Compensation

    B

    73/100

Learn more on Comparably

Intersect ENT Blogs

Intersect ENT Announces Preliminary Revenue for Fourth Quarter of 2020

- Preliminary Unaudited Fourth Quarter 2020 Revenue Expected to be $27.7 to $28.1 Million - MENLO PARK, Calif. --(BUSINESS WIRE)--Jan. 12, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today

CORRECTING and REPLACING - Intersect ENT to Present at the 39th Annual J.P. Morgan Healthcare Conference

MENLO PARK, Calif. --(BUSINESS WIRE)--Dec. 17, 2020-- Presentation time in the release dated December 17, 2020 , should read 2 p.m. ET (instead of 5 p.m. ET ). The updated release reads: INTERSECT ENT TO PRESENT AT THE 39 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Intersect ENT, Inc.

Intersect ENT to Present at the 39th Annual J.P. Morgan Healthcare Conference

MENLO PARK, Calif. --(BUSINESS WIRE)--Dec. 17, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that management will participate in the 39 th Annual J.P. Morgan Healthcare Conference .

Intersect ENT Announces New Appointments to Executive Leadership Team

Intersect ENT Announces New Appointments to Executive Leadership Team Content Import Tue, 11/17/2020 - 16:45 Intersect ENT Announces New Appointments to Executive Leadership Team Nov 17, 2020 This release is a backfill from a News Wire Fi…

Intersect ENT to Participate at Upcoming Investor Conferences

Intersect ENT to Participate at Upcoming Investor Conferences Content Import Thu, 11/05/2020 - 16:09 Intersect ENT to Participate at Upcoming Investor Conferences Nov 05, 2020 This release is a backfill from a News Wire Financial Releases…

Intersect ENT Reports Third Quarter 2020 Financial Results

Intersect ENT Reports Third Quarter 2020 Financial Results Content Import Mon, 11/02/2020 - 07:01 Intersect ENT Reports Third Quarter 2020 Financial Results Nov 02, 2020 This release is a backfill from a News Wire Financial Releases …
Show more

Intersect ENT Frequently Asked Questions

  • When was Intersect ENT founded?

    Intersect ENT was founded in 2003.

  • Who are Intersect ENT key executives?

    Intersect ENT's key executives are Thomas A. West, Patrick Broderick and Reyna Fernandez.

  • How many employees does Intersect ENT have?

    Intersect ENT has 402 employees.

  • What is Intersect ENT revenue?

    Latest Intersect ENT annual revenue is $109.1 m.

  • What is Intersect ENT revenue per employee?

    Latest Intersect ENT revenue per employee is $271.5 k.

  • Who are Intersect ENT competitors?

    Competitors of Intersect ENT include Medizone International, ResMed and Pressure BioSciences.

  • Where is Intersect ENT headquarters?

    Intersect ENT headquarters is located at 1555 Adams Dr, Menlo Park.

  • Where are Intersect ENT offices?

    Intersect ENT has an office in Menlo Park.

  • How many offices does Intersect ENT have?

    Intersect ENT has 1 office.